Richard E. Lee
20Patents
3h-index
47Co-inventors
59Inventor score
Filing activity: May 17, 2002 → Apr 15, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6951961B2 | Methods of use and compositions for the diagnosis and treatment of infectious disease | Chemistry; Metallurgy | 8 | Expired |
| US7456222B2 | Anti tubercular drug: compositions and methods | Emerging Cross-Sectional Technologies | 7 | Expired |
| US10266544B2 | Aryl substituted aminomethyl spectinomycin analogs as antibacterial agents | Human Necessities | 4 | Active |
| US7842729B2 | Anti tubercular drug: compositions and methods | Emerging Cross-Sectional Technologies | 2 | Expired |
| US10100090B2 | Substituted urea depsipeptide analogs as activators of the CLPP endopeptidase | Emerging Cross-Sectional Technologies | 2 | Active |
| US8552208B2 | Analogs of tetramic acid | Chemistry; Metallurgy | 2 | Active |
| US9593136B2 | Compounds for inhibiting 1-deoxy-D-xylulose-5-phosphate reductoisomerase | Physics | 2 | Active |
| US10899734B2 | Small molecule modulators of pantothenate kinases | Chemistry; Metallurgy | 2 | Active |
| US9879050B2 | Substituted urea depsipeptide analogs as activators of the CLPP endopeptidase | Emerging Cross-Sectional Technologies | 2 | Active |
| US8685978B2 | Spectinamides as anti-tuberculosis agents | Human Necessities | 1 | Active |
| US9284325B2 | Spectinamides as anti-tuberculosis agents | Human Necessities | 0 | Active |
| US10570179B2 | Substituted urea depsipeptide analogs as activators of the CLPP endopeptidase | Human Necessities | 0 | Active |
| US11891378B2 | Small molecule modulators of pantothenate kinases | Human Necessities | 0 | Active |
| US10011589B2 | Treatments for gastrointestinal conditions | Chemistry; Metallurgy | 0 | Active |
| US10457707B2 | Substituted urea depsipeptide analogs as activators of the CLPP endopeptidase | Emerging Cross-Sectional Technologies | 0 | Active |
| US10676510B2 | Substituted urea depsipeptide analogs as activators of the ClpP endopeptidase | Emerging Cross-Sectional Technologies | 0 | Active |
| US8268894B2 | Compositions and methods for the treatment of infectious diseases | Emerging Cross-Sectional Technologies | 0 | Active |
| US12115225B2 | GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US11547709B2 | Methods of treating disorders associated with castor | Human Necessities | 0 | Active |
| US10822377B2 | Substituted urea depsipeptide analogs as activators of the ClpP endopeptidase | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.